Falcone, Mattia http://orcid.org/0000-0003-0906-5735
Uribe, Alejandro Huerta
Papalazarou, Vasileios
Newman, Alice C.
Athineos, Dimitris
Stevenson, Katrina
Sauvé, Charles-Etienne Gabriel
Gao, Yajing
Kim, Jin K. http://orcid.org/0000-0002-4373-1431
Del Latto, Michael
Kierstead, Maria
Wu, Chao
Smith, J. Joshua http://orcid.org/0000-0003-2538-5456
Romesser, Paul B.
Chalmers, Anthony J. http://orcid.org/0000-0002-1746-7278
Blyth, Karen http://orcid.org/0000-0002-9304-439X
Maddocks, Oliver D. K. http://orcid.org/0000-0002-5551-9091
Funding for this research was provided by:
European Molecular Biology Organization (ALTF 276-2019)
Cancer Research UK (C53309/A19702, C53309/A19702, A29799, A17196, C16583/A28803, A17196, A29799, C53309/A19702)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30 CA008748, R37 CA248289, K08 CA255574)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Article History
Received: 18 February 2022
Revised: 10 August 2022
Accepted: 19 August 2022
First Online: 17 September 2022
Competing interests
: ODKM contributed to CRUK Cancer Research Technology filing of UK Patent Application no. 1609441.9, relating to dietary modulation of amino acids, and is a co-founder, shareholder and board member of Faeth Therapeutics. JJS received travel support from Intuitive Surgical Inc. (2015) and served as a clinical advisor for Guardant Health Inc. (2019). PBR reports prior research funding from EMD Serono.
: No human subjects participated in this study. The rectal cancer patient-derived organoid biorepository at MSK is prospectively maintained by JJS and CW and is under the approved institutional review board protocol for JJS (#16-1071). All patients provided informed consent for use of tissue.
: Not applicable.